GlobeNewswire by notified

Avance Gas Holding Ltd (AGAS): Successfully completed the sale of our fifth VLGC newbuilding

Share

Hamilton, Bermuda
March 19, 2024

Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) announce today the successful sale of newbuilding hull 2367 with intended name Avance Castor for a cash consideration of $120 million less broker commission as previously announced in a press release dated December 8, 2023.

The Company expect to record a book gain on sale and cash release following repayment of bank financing of $36 million and $61 million respectively.

The sale of the sister ship, newbuilding hull 2368 with intended name Avance Pollux, is scheduled to take place in the first half of May 2024. This sale is also expected to result in a book gain and cash release of $36 million and $60 million respectively.

For further queries, please contact:
Media contact: Øystein Kalleklev, CEO Tel: +47 23 11 40 00

Investor and Analyst contact:
Randi Navdal Bekkelund, CFO Tel: +47 23 11 40 00

ABOUT AVANCE GAS
Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs) and owns sixteen LPG VLGC ships consisting of twelve modern VLGCs including four dual fuel LPG VLGCs and four dual fuel MGCs for delivery in 2025 and 2026.

For more information about Avance Gas, please visit www.avancegas.com.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders17.4.2024 02:00:00 CEST | Press release

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A. Registered Address: 2, Rue du Fort Bourbon L-1249 Luxembourg, Grand Duchy of Luxembourg – R.C.S. Luxembourg: B 40.630 – I. NOTICE The annual general meeting (“AGM”) and subsequent extraordinary general meeting (“EGM”) of the shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (“Millicom” or the “Company”) is hereby convened to be held at Hotel Le Royal, 12 Bd Royal, 2449 Luxembourg on Thursday, May 23, 2024, at 11:00 a.m. Central European Time ("CET"). To attend the AGM and EGM or vote by proxy, please follow the instructions in section IV: “Right to participate at the AGM and the EGM”. The AGM and EGM will consider and vote on the agenda points listed below. Please refer to section IX: “Notes to the Agenda Points of the AGM and EGM” to find detailed information about these proposals. II. AGENDA AGM To elect the chair of the AGM and to empower the chair of

Millicom’s Nomination Committee’s proposal for Board of Directors17.4.2024 02:00:00 CEST | Press release

Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, April 17, 2024 – In advance of the Annual General Meeting of shareholders (“AGM”) of Millicom International Cellular S.A. (“Millicom”), to be held on May 23, 2024, Millicom’s Nomination Committee proposes: The election of Maxime Lombardini and Justine Dimovic as new Directors of the Board; The re-election of María Teresa Arnal Machado, Bruce Churchill, Aude Durand, Tomas Eliasson, Mauricio Ramos, Thomas Reynaud, and Blanca Treviño de Vega as Directors of the Board; and the election of Mauricio Ramos as Chair of the Board. Pernille Erenbjerg and Michael Golan have decided not to seek re-election. Maxime Lombardini will bring his extensive experience and track record in leading businesses in the telecommunications industry, as well as the strong knowledge of Millicom that he has gained while serving as President and Chief Operating Officer since September 2023. Justine Dimovic will bring a wealth of capital all

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

HiddenA line styled icon from Orion Icon Library.Eye